Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551416 | 1.00 | KDM4E (0.44) | KDM4EGAANNMTMAPTLMNA | |
| SCHEMBL31280472 | 0.88 | NNMT (0.41) | KDM4EGAANNMTMAPTLMNA | |
| SCHEMBL29416286 | 0.87 | KDM4E (0.49) | KDM4EGAAMAPTLMNAMAPK1 | |
| SCHEMBL977733 | 0.87 | KDM4E (0.49) | KDM4EGAAMAPTLMNAMAPK1 | |
| SCHEMBL236107 | 0.85 | KDM4E (0.47) | KDM4EGAAMAPTLMNAMAPK1 | |
| SCHEMBL30217866 | 0.85 | KDM4E (0.47) | KDM4EGAAMAPTLMNAMAPK1 | |
| SCHEMBL24773853 | 0.84 | CA12 (0.49) | KDM4EGAAMAPTLMNAMAPK1 | |
| SCHEMBL31387954 | 0.84 | CA12 (0.49) | KDM4EGAAMAPTLMNAMAPK1 | |
| SCHEMBL8495483 | 0.84 | GAA (0.42) | KDM4EGAANNMTMAPTLMNA | |
| SCHEMBL31444292 | 0.84 | NNMT (0.44) | KDM4EGAANNMTMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 849 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161297-A | Preparation method of 4-bromo-6-chloronicotinic acid methyl ester | 浙江工业大学 | 2024-12-20 | — | — | CN | claimed |
| CN-106854177-B | A kind of preparation method of 6- chloro-4-hydroxyl pyridine -3- formaldehyde | 苏州健雄职业技术学院 | 2019-10-11 | — | — | CN | claimed |
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12583839-B2 | PD-L1 antagonist compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | NURIX THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2005028452-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004043925-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2002076463-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| US-5077429-A | 7-AMINO-1-CYCLOPROPYL-4-OXO-1,4-DIHYDRO-QUINOLINE- AND NAPHTHYRIDINE-3-CARBOXYLIC ACIDS, PROCESSES FOR THEIR PREPARATION AND ANTIBACTERIAL AGENTS CONTAINING THESE COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1991-12-31 | — | — | US | disclosed |
| US-4670444-A | 7-amino-1-cyclopropyl-4-oxo-1, 4-dihydro-quinoline-and naphthyridine-3-carboxylic acids and antibacterial agents containing these compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1987-06-02 | — | — | US | disclosed |
| US-4620007-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1986-10-28 | — | — | US | disclosed |
| EP-0049355-B1 | 7-Amino-1-cyclopropyl-4-oxo-1,4-dihydro-(naphthyridine or quinoline)-3-carboxylic acids, process for their preparation and pharmaceutical compositions containing them | BAYER AG (DE) | 1984-10-10 | — | — | EP | disclosed |
| EP-0049355-A1 | 7-Amino-1-cyclopropyl-4-oxo-1,4-dihydro-(naphthyridine or quinoline)-3-carboxylic acids, process for their preparation and pharmaceutical compositions containing them | BAYER AG (DE) | 1982-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | IRAK1, IRAK2, IRAK4 | KDM4E 1263/4885GAA 3723/4885NNMT 2534/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | KDM4E 4515/4885GAA 477/4885NNMT 2435/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | KDM4E 3153/4885GAA 3019/4885NNMT 2469/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | KDM4E 315/4885GAA 3067/4885NNMT 2042/4885 |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, GLP1R | KDM4E 1542/4885GAA 3109/4885NNMT 2937/4885 |
| US-12583839-B2 | PD-L1 antagonist compound | CD274, PDCD1LG2, PDCD1 | KDM4E 2998/4885GAA 4247/4885NNMT 1838/4885 |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | C3AR1, C5AR1, C5AR2 | KDM4E 2711/4885GAA 4839/4885NNMT 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.